Source: Eur Respir J 2006; 27: 1010-1019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Aspa J., Rajas O., Rodriguez de Cast... F., Huertas M. C., Borderias L., Cabello F. J., Tabara J., Hernandez-Flix S., Martinez-Sanchis A., Torres A.. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27: 1010-1019

Member's Comments

No comment yet.

Related content which might interest you: S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistance Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008 Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 Streptococcus pneumoniae resistance pattern and its clinical implications Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia Source: Eur Respir J 2010; 36: 1073-1079 Year: 2010 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP) Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005 Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes Source: Eur Respir J 2014; 43: 545-553 Year: 2013 Pulmonary disease as a risk factor for community-acquired pneumonia caused by multiple pathogens, including Streptococcus pneumoniae Source: Eur Respir J 2001; 18: Suppl. 33, 502s Year: 2001 Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Source: Eur Respir J 2004; 24 : 779-785 Year: 2004 Levofloxacin non-susceptible streptococcus pneumoniae in community-acquired respiratory infection; prevalence and risk factors Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia Source: Eur Respir J 2006 Oct 01;28(4):816-823 Year: 2006 Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 The impact of antibiotic resistance in the management of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=131 Year: 2004 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004